Modern strategies in therapy of elderly patients with multiple myeloma

QR Code

Modern strategies in therapy of elderly patients with multiple myeloma

We used the bortezomib plus dexamethasone (VD) and bortezomib plus MP (VMP) in 56 previously untreated elderly patients with multiple myeloma. The patients were 65–89 years old. For patients who received bortezomib plus MP the overall response rate was 83%. 33.3% of patients achieved complete respon...

Full description

Saved in:

Bibliographic Details
Main Authors:	S. S. Bessmeltsev, L. V. Stelmashenko, E. V. Kariagina, N. V. Stepanova, G. N. Salogub, T. L. Shelkovskaya, T. A. Malakhova, I. A. Skorokhod, E. I. Podoltseva, N. O. Saraeva, O. I. Kovalev, A. V. Klimovich, N. V. Medvedeva, K. M. Abdulkadyrov, L. I. Krylova, T. H. Potrachkova, M. A. Novikova, E. R. Machulaitene, E. I. Darskaya, L. M. Matukhina, N. A. Kotova, O. Ya. Kostina, I. A. Novokreshchenova
Format:	Article
Language:	Russian
Published:	ABV-press 2022-11-01
Series:	Онкогематология
Subjects:	bortezomib multiple myeloma treatment complete remission overall survival neuropathy
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/757
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Chemoresistance of PRAME-expressing melanoma cell can be resolved with help of bortezomib
by: V. A. Misyurin, et al.
Published: (2019-01-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01)

BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
by: A. S. Kolbin, et al.
Published: (2015-06-01)

Successful experience of venetoclax in the treatment of refractory primary plasma cell leukemia
by: I. V. Cherkashina, et al.
Published: (2025-03-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)

The role of АВС transporters in drug resistance to bortezomib in multiple myeloma
by: L. A. Laletina, et al.
Published: (2019-04-01)

Macrocusteio do uso do Bortezomibe no tratamento do Mieloma Múltiplo na perspectiva do SUS
by: Mariana Andrades Fiorini Monteiro Novo, et al.
Published: (2025-07-01)

The importance of preexisting drug resistance due to overexpression of P-glycoprotein for the formation of resistance to bortezomib
by: L. A. Laletina, et al.
Published: (2020-03-01)

<i>PRAME, WT1</i> and <i>XIAP</i> tumor-associated genes expression in multiple myeloma patients
by: T. V. Gaponova, et al.
Published: (2022-11-01)

New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma
by: M. А. Sorokina, et al.
Published: (2023-07-01)

Bortezomib and quercetin as effective modulators of lipopolysaccharide-induced systemic inflammatory response and metabolic disorders
by: Ye. O. Morhun, et al.
Published: (2025-06-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Targeted Delivery of Bortezomib Using Retinoid-Based Nanoparticle: Modulating Liver Fibrosis through the TGF-β1/Smad3 Pathway
by: Samaneh Siapoush, et al.
Published: (2025-04-01)

Bortezomib-based Chemotherapy and Bone-marrow Followed by Renal Transplantation in Multiple Myeloma: A Literature Review
by: Jasmine Sethi, et al.
Published: (2025-04-01)

The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia
by: Camila Terreros-Palacios, et al.
Published: (2025-07-01)

FmocFF Peptide Hydrogel Is a Promising Matrix for Encapsulation and Controlled Release of the Anticancer Peptide Drug Bortezomib
by: Peter Divanach, et al.
Published: (2025-06-01)

Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research)
by: E. I. Kankumasheva, et al.
Published: (2020-01-01)

Moving Beyond G‐CSF Mobilization—Learning From a 15‐Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma
by: Sumeet Mirgh, et al.
Published: (2025-07-01)

Proteasome inhibitors: situation and prospects (literature review and own data)
by: A. A. Rukavitsyn, et al.
Published: (2016-10-01)

Bortezomib-induced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects
by: E. Z. Irugova, et al.
Published: (2025-03-01)

Influence of TNF-alpha on the efficacy of anemia correction in patients with lymphoproliferative disorders
by: N. A. Romanenko, et al.
Published: (2022-11-01)

DEVELOPMENT AND VALIDATION OF METHOD FOR POTENTIOMETRIC DETERMINATION OF SILVER IN PHARMACEUTICAL SUBSTANCE «ARGAMID»
by: N. S. Skosyreva, et al.
Published: (2019-01-01)

Invasive Mucormycosis in Patients with Hemoblastosis in St.-Petersburg
by: S. N. Khostelidi, et al.
Published: (2020-05-01)

RELATIONSHIP BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS IN CYTOKINE GENES AND CLINICAL LABORATORY PARAMETERS IN PATIENTS WITH MULTIPLE MYELOMA
by: A. A. Pavlova, et al.
Published: (2019-10-01)

Genetic features of the killer cell immunoglobulin-like receptors in the haematopoietic stem cell donors
by: Iu. V. Sokolova, et al.
Published: (2014-07-01)

First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphoma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

MUCORMYCOSIS IN ONCOHEMATOLOGY PATIENTS (results of the prospective study)
by: N. N. Klimko, et al.
Published: (2017-06-01)